Save
Email
Print
ShareSep. 3, 2009 — X-linked nephrogenic diabetes insipidus (XNDI) is a severe congenital kidney disease caused by mutations in the V2R gene. Currently, there is no effective drug to specifically treat XNDI, mainly because there are no good animal models of the disease.
However, Jürgen Wess and colleagues, at the National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, have now developed a viable mouse model of XNDI that recapitulates the major manifestations of the human disease. The research appears in the Sept. 1, 2009 issue of the Journal of Clinical Investigation.
As analysis of the mouse model indicated that disease was associated with increased expression in the kidney of the protein EP4, the authors tested selective EP4 receptor agonists as potential therapeutics, and found that they alleviated all the symptoms of disease.
The authors therefore suggest that selective EP4 receptor agonists could be of benefit to individuals with XNDI and hope that their mouse model can be used to test additional new therapeutic strategies.
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by Journal of Clinical Investigation, via EurekAlert!, a service of AAAS.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Journal Reference:
- Jian Hua Li et al. A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus. Journal of Clinical Investigation, 2009; DOI: 10.1172/JCI39680
Note: If no author is given, the source is cited instead.
more 
